To validate the synergistic effect of DNA2 inhibitor d16 and PARPi in vivo, we established ovarian cancer MDAH-2774 xenografts in NSG mice and treated the mice with vehicle control, d16 (20 mg/kg, i.p. injection, twice/week), talazoparib (0.5 mg/kg, i.p. injection, daily 5×/week), or both. This evidence concerns the gene DNA2 and ovarian carcinoma.